Home » Newsletters » BioWorld Science

BioWorld Science

April 2, 2012

View Archived Issues

Novel acetyl-CoA carboxylase 2 inhibitors presented

Taisho reports novel phosphodiesterase 10A inhibitors

Janssen discloses new serotonin 5-HT2B receptor antagonists

Data presented from TRACER and TRAP2P-TIMI 50 vorapaxar trials

Immunotherapy potently reduces LDL cholesterol in phase I trials

Transient receptor potential TRPV1 channel antagonist well tolerated in healthy volunteers

PharmaNeuroBoost clear to commence proof-of-concept PNB-02 trial

Omadacycline noninferior to linezolid in phase III trial

Shionogi and OncoTherapy Science expand licensing agreement

Allergan obtains rights for Ameluz in Spain

ImmunoGen begins phase II IMGN-901 study

Preclinical data support entry of ABTL-0812 into the clinic

ViroMed clear to conduct head-to-head phase III VM-501 study

Roche reports topline data from phase III EMILIA trial

TH-302 gets orphan drug status in E.U. and U.S.

Myriad Genetics and Cephalon enter agreement for mutation testing in phase I/II study

Cardium Therapeutics launches wound care product in U.S.

Portola begins pivotal study of its factor Xa inhibitor

Kyowa Hakko Kirin files application for approval of Parkinson's disease treatment in Japan

Roche divulges novel HDL cholesterol-increasing agents

Novel GCS activators patented by Bayer Schering

First three phase III QVA-149 studies meet primary endpoints

GSK seeks Japanese approval for combination tablet to prevent and treat malaria

Minophagen granted additional rights to bexarotene

Novartis seeks approval for Lucentis line extension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...